Knowledge Hub

Why Intellectual Property Strategy Matters for API Manufacturers
Why Intellectual Property Strategy Matters for API Manufacturers

In today's highly competitive pharmaceutical landscape, intellectual property (IP) is no longer just a legal safeguard – it's a core business strategy. For API manufacturers, IP considerations influence everything from early research decisions to long-term commercial viability. As drug pipelines become more complex and timelines more compressed, a well-defined IP strategy can be the difference between sustainable growth and costly setbacks.

Feb 16, 2026

The Future of Pharma: Digitally Connected CDMO and Biologics Operations
The Future of Pharma: Digitally Connected CDMO and Biologics Operations

Across the pharmaceutical industry, digital connectivity is reshaping how therapies are developed, manufactured, and delivered. As pipelines grow more complex and timelines compress, companies are increasingly relying on CDMO pharma partners that can integrate data, systems, and workflows across development and manufacturing. Digitally connected operations are no longer a future ambition; they are becoming a prerequisite for efficient, resilient CDMO drug development.

Feb 09, 2026

Developing Peptide APIs at Scale: Technologies Driving Efficiency and Quality
Developing Peptide APIs at Scale: Technologies Driving Efficiency and Quality

Peptide-based therapeutics are increasingly critical in modern drug development. Positioned between small molecules and biologics, peptides offer strong target specificity, favorable safety profiles, and wide therapeutic potential. As more peptide candidates advance from discovery to clinical and commercial stages, the ability to develop and manufacture peptide APIs efficiently, at scale, and with consistent quality has become essential.

Feb 06, 2026

Advancing ADC Analytical Development in a Rapidly Evolving Pharma Landscape
Advancing ADC Analytical Development in a Rapidly Evolving Pharma Landscape

Antibody-drug conjugates (ADCs) represent a cutting-edge approach to targeted therapy, uniting the precision of antibodies with the powerful effects of cytotoxic drugs. As these sophisticated molecules become increasingly important in oncology and other therapeutic fields, their development depends on advanced analytical expertise. ADC pharma programs are highly complex, requiring meticulous characterization, stringent quality control, and comprehensive bioanalytical services to ensure success.

 

Feb 03, 2026

How High - Throughput Experimentation Accelerates Drug Development
How High - Throughput Experimentation Accelerates Drug Development

Speed, efficiency, and smart use of limited materials are constant pressures in early drug development. High-throughput experimentation (HTE) has emerged as a powerful way for drug developers to address these challenges by rapidly exploring reaction conditions and generating actionable data that supports downstream scale-up.

Jan 30, 2026

Thank You for your Interest. Please enter your details.
Thank You for your Interest. Please enter your details.
Thank You for your Interest. Please enter your details.
loader